|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
The purpose of this Phase 2 study is to assess the pharmacokinetics (PK) and safety of RLYB212 in HPA-1b/b pregnant women at higher risk for HPA-1a alloimmunization and FNAIT.
100 项与 Rallybio IPA LLC 相关的临床结果
0 项与 Rallybio IPA LLC 相关的专利(医药)
100 项与 Rallybio IPA LLC 相关的药物交易
100 项与 Rallybio IPA LLC 相关的转化医学